SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violat...
June 28 2016 - 11:04AM
Business Wire
Levi & Korsinsky announces it has commenced an investigation
of Regulus Therapeutics Inc. (“Regulus” or the “Company”) (NASDAQ:
RGLS) concerning possible violations of federal securities
laws.
On June 27, 2016, Regulus announced receipt of verbal notice
from the U.S. Food and Drug Administration that its investigational
new drug for the treatment of chronic hepatitis C infection has
been placed on a clinical hold. According to Regulus, the hold was
a result of a second serious adverse event of jaundice in a patient
enrolled in the drug’s on-going Phase I US study. Following this
news, shares of Regulus were down more than 47% on intraday trading
on June 28, 2016. To obtain additional information about the
investigation, go to:
http://zlk.9nl.com/regulus-therapeutics-rgls
or contact Eduard Korsinsky, Esq. either via email at ek@zlk.com
or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New
York, New Jersey, California, Connecticut, and Washington D.C. The
firm’s attorneys have extensive expertise and experience
representing investors in securities litigation involving financial
fraud, and have recovered hundreds of millions of dollars for
aggrieved shareholders. Attorney advertising. Prior results do not
guarantee similar outcomes.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160628006078/en/
Levi & Korsinsky, LLPEduard Korsinsky, Esq.Tel: (212)
363-7500Toll Free: (877) 363-5972Fax: (212) 363-7171www.zlk.com
Regulus Therapeutics (NASDAQ:RGLS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Regulus Therapeutics (NASDAQ:RGLS)
Historical Stock Chart
From Jul 2023 to Jul 2024